Feedback on proposed changes to ADHD prescriber rules

About this form

This is a joint agency consultation. Medsafe will review your feedback to the Medsafe questions and Pharmac will review the Pharmac questions. This means we will pass any personal information you include to Medsafe.

Please note:

You cannot save your progress.
The form does not register text formatting, such as bold or hyperlinks.
There is no character limit on any field.
You will receive an email with a summary of your feedback when you submit the form.
Unless otherwise stated, all questions are optional.

Changes proposed by Medsafe

Do you have any feedback on the proposal to allow nurse practitioners (working within paediatric services or child and adolescent mental health services) to start stimulant treatment, for people with ADHD 17 years and under?

Do you have any feedback on the proposal to allow medical practitioners (with a vocational scope in general practice) to start prescribing, for people with ADHD 18 years and over?

Do you have any feedback on the proposal to allow nurse practitioners (working within their scope of practice) to start prescribing, for people with ADHD 18 years and over?

Do you have any feedback on the proposal to allow different prescribers to start stimulant treatment based on the age of the person with ADHD?

Do you have any feedback on any defined training requirements that vocationally registered GPs or nurse practitioners would be expected to complete before diagnosing someone with ADHD and starting them on stimulant medicine?

Do you have any other comments on the proposed changes to the restrictions for stimulant treatments for Medsafe?

Changes proposed by Pharmac

Do you have any feedback about the proposal and the impact for clinicians or people with ADHD or who may have ADHD? (optional)

Do you have any feedback on the benefits and the risks of this proposal?

Do you have any feedback on the Special Authority access criteria for stimulant treatments?

Clinicians:

Do you have any feedback on implementation activities that would be required to support prescribers with this proposal?

For example, training, education, practical resources, and resourcing

People with or who may have ADHD or who care for people with ADHD:

Do you have any feedback on implementation activities that would be required to support access to stimulant treatment for ADHD?

Such as, how to easily find prescribers who can assess and diagnose ADHD, how will access be supported, updated information on Healthify to understand the changes.

About you

Your name

Your email address

An email is required. If you don't want to give an email, you can leave the default email

Your role

Your organisation

Your feedback may be shared

We may share your feedback anonymously with organisations that support prescribers, like Health New Zealand | Te Whatu Ora.

In addition, when you give feedback on a consultation, your feedback becomes official information that Pharmac holds. Pharmac has legal responsibilities for how we manage this official information, under laws such as the Official Information Act and Privacy Act.

Pharmac may receive a request from people for official information, which could include your feedback. Legally, Pharmac must consider whether your feedback should be released.

We will consider your views when assessing whether the feedback has to be released.

If your feedback is proposed for release, then Pharmac will contact you, unless there is a legal reason that we can't.

Note that Pharmac collects and holds your information in line with our Privacy Statement.

Tell us if there is anything about your feedback that you would prefer wasn’t released.